PT - JOURNAL ARTICLE AU - Raymond L. Benza AU - David Langleben AU - Anna R. Hemnes AU - Anton Vonk Noordegraaf AU - Stephan Rosenkranz AU - Thenappan Thenappan AU - Paul M. Hassoun AU - Ioana R. Preston AU - Stefano Ghio AU - Roberto Badagliacca AU - Carmine D. Vizza AU - Irene M. Lang AU - Christian Meier AU - Ekkehard GrĂ¼nig TI - Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension AID - 10.1183/16000617.0061-2022 DP - 2022 Dec 31 TA - European Respiratory Review PG - 220061 VI - 31 IP - 166 4099 - http://err.ersjournals.com/content/31/166/220061.short 4100 - http://err.ersjournals.com/content/31/166/220061.full SO - EUROPEAN RESPIRATORY REVIEW2022 Dec 31; 31 AB - Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.Raymond L. Benza (@OSUWexMed) and co-authors review the current evidence showing the effect of riociguat on right ventricle remodelling, function and structural parameters in preclinical models and patients with #PAH or #CTEPH. #pulmonaryhypertension https://bit.ly/3Q9icVm